These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18774415)

  • 1. Abacavir and increased risk of myocardial infarction.
    Edwards R; Bate A; Lindquist M
    Lancet; 2008 Sep; 372(9641):805. PubMed ID: 18774415
    [No Abstract]   [Full Text] [Related]  

  • 2. Abacavir and the potential risk of myocardial infarction.
    Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
    Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
    [No Abstract]   [Full Text] [Related]  

  • 3. Abacavir and increased risk of myocardial infarction.
    Goicoechea M; McCutchan A
    Lancet; 2008 Sep; 372(9641):803-4; author reply 804-5. PubMed ID: 18774413
    [No Abstract]   [Full Text] [Related]  

  • 4. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 5. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
    Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
    HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir and cardiovascular risk.
    Behrens GM; Reiss P
    Curr Opin Infect Dis; 2010 Feb; 23(1):9-14. PubMed ID: 19996748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
    Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
    Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir and increased risk of myocardial infarction.
    Post FA; Campbell LJ
    Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412
    [No Abstract]   [Full Text] [Related]  

  • 10. Abacavir and cardiovascular risk: reviewing the evidence.
    Costagliola D; Lang S; Mary-Krause M; Boccara F
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):127-33. PubMed ID: 20521126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abacavir, Didanosine: myocardial infarction.
    Prescrire Int; 2008 Dec; 17(98):244. PubMed ID: 19431227
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Controversial findings on abacavir and heart attacks.
    TreatmentUpdate; 2008 Mar; 20(2):1-5. PubMed ID: 18661643
    [No Abstract]   [Full Text] [Related]  

  • 13. Abacavir controversy continues to brew.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):4-7. PubMed ID: 19043874
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA notifications. Ongoing safety review of abacavir, possible MI risk.
    AIDS Alert; 2011 May; 26(5):58-9. PubMed ID: 21649950
    [No Abstract]   [Full Text] [Related]  

  • 15. Abacavir and cardiovascular disease: A critical look at the data.
    Llibre JM; Hill A
    Antiviral Res; 2016 Aug; 132():116-21. PubMed ID: 27260856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance].
    Walter M
    MMW Fortschr Med; 2009 Apr; 151(18):76-9. PubMed ID: 19769084
    [No Abstract]   [Full Text] [Related]  

  • 17. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
    Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
    AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.
    AIDS Alert; 2008 May; 23(5):58-9. PubMed ID: 18642404
    [No Abstract]   [Full Text] [Related]  

  • 19. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.
    Kowalska JD; Kirk O; Mocroft A; Høj L; Friis-Møller N; Reiss P; Weller I; Lundgren JD
    HIV Med; 2010 Mar; 11(3):200-8. PubMed ID: 19863618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir hypersensitivity reaction.
    Hewitt RG
    Clin Infect Dis; 2002 Apr; 34(8):1137-42. PubMed ID: 11915004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.